Company intelligence / Profile preview

Nabla Bio

Cambridge, Massachusetts, United Statesnabla.com ↗

Ownership: Private
Development stage: Other

Overview

Nabla Bio has demonstrated that its generative protein design platform can create antibodies, novel cytokines, multi-domain antibodies, and receptor traps with improved in vitro activity and developability compared to leading drugs. The company’s technology enables targeting of previously inaccessible multipass membrane proteins. No clinical trial results have been published as of June 2025.

Therapeutic areas: Rare DiseasesImmunology
Modalities: Monoclonal antibodyMulti-domain antibodyCytokineRecombinant protein
Industry: Biotech

Partnerships

AstraZenecaBristol Myers SquibbTakeda

Beyond the preview

Go deeper on Nabla Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nabla Bio.

Explore the full profile